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Abstract
Context: Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD
represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH)
and cirrhosis. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD is highlighted in patients with GC
excess, Cushing’s syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most
cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate
cortisol (F) from inactive cortisone (E) (11b-hydroxysteroid dehydrogenase type 1, 11b-HSD1), or inactivate cortisol through
A-ring metabolism (5a- and 5b-reductase, 5aR and 5bR).
Objective and Methods: In vitro studies defined 11b-HSD1 expression in normal and NASH liver samples. We then
characterised hepatic cortisol metabolism in 16 patients with histologically proven NAFLD compared to 32 obese controls
using gas chromatographic analysis of 24 hour urine collection and plasma cortisol generation profile following oral
cortisone.
Results: In patients with steatosis 5aR activity was increased, with a decrease in hepatic 11b-HSD1 activity. Total cortisol
metabolites were increased in this group consistent with increased GC production rate. In contrast, in patients with NASH,
11b-HSD1 activity was increased both in comparison to patients with steatosis, and controls. Endorsing these findings, 11b-
HSD1 mRNA and immunostaining was markedly increased in NASH patients in peri septal hepatocytes and within CD68
positive macrophages within inflamed cirrhotic septa.
Conclusion: Patients with hepatic steatosis have increased clearance and decreased hepatic regeneration of cortisol and we
propose that this may represent a protective mechanism to decrease local GC availability to preserve hepatic metabolic
phenotype. With progression to NASH, increased 11b-HSD1 activity and consequent cortisol regeneration may serve to limit
hepatic inflammation.
Citation: Ahmed A, Rabbitt E, Brady T, Brown C, Guest P, et al. (2012) A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver
Disease. PLoS ONE 7(2): e29531. doi:10.1371/journal.pone.0029531
Editor: Jean-Marc A. Lobaccaro, Clermont Universite´, France
Received May 17, 2011; Accepted November 30, 2011; Published February 20, 2012
Copyright:  2012 Ahmed et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the Wellcome Trust (Programme Grant reference number is 082809/Z/07/Z) (to P.M.S.) Medical Research
Council G84/6638 (to A.A.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: p.m.stewart@bham.ac.uk
Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic
manifestation of the metabolic syndrome and is now acknowl-
edged to be the commonest liver problem of the western world,
and the leading cause of cryptogenic cirrhosis. NAFLD represents
a spectrum of liver disease ranging from simple and reversible
hepatic steatosis, to non alcoholic steato-hepatitis (NASH) where
there is evidence of inflammation culminating in cirrhosis with
liver failure, and hepatocellular carcinoma. It is rapidly becoming
the leading indication for liver transplantation. Critically, the
histological diagnosis at presentation predicts prognosis in these
patients. Those with simple fatty liver at presentation only have a
2% risk of progressing to end stage cirrhosis in a 20 year period.
However when there is evidence of steatohepatitis or fibrosis, the
risk of developing cirrhosis is up to 50% in a 2 year period [1]. The
pathogenesis of NAFLD is poorly understood but several factors
are thought to be important, including insulin resistance, obesity
and type 2 diabetes; 90% of patients with NAFLD cirrhosis having
obesity and/or diabetes mellitus.
Patients with the metabolic syndrome share many phenotypic
features with Cushing’s syndrome (e.g. hypertension, abdominal
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obesity, insulin resistance and impaired glucose tolerance). Indeed,
20% of patients with Cushing’s syndrome have NAFLD [2], and
there are a number of reports that implicate pharmacological
glucocorticoid (GC) excess in hepatic triglyceride accumulation
[3,4]. Glucocorticoids promote steatosis by directly stimulating
hepatic de novo lipogenesis and free fatty acid (FFA) utilization [5–
7], and by promoting lipolysis within omental fat, resulting in
increased portal FFA delivery to the liver [8]. Cushing’s syndrome
is rare and the vast majority of patients with NAFLD have normal
circulating cortisol levels. However, local GC concentrations
within key metabolic target tissues are controlled at the pre-
receptor level through a series of enzymes; 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1), interconverting hormonally
inactive cortisone (E) to active cortisol (F) and, 5a and 5b
reductases (5aR and 5bR) which inactivate cortisol to the dihydro
and subsequently tetrahydro metabolites (THF or 5aTHF). Our
previous work has shown that in simple obesity, there is a
reduction in the generation of serum cortisol from dexamethasone-
suppressed values after the administration of oral cortisone
reflecting decreased hepatic 11b-HSD1 activity [9]. This comes
at a time of interest in the concept of selective 11b-HSD1
inhibition as a novel therapy for patients with the metabolic
syndrome – inhibition of hepatic and adipose cortisol regeneration
resulting in reduced gluconeogenesis and adipogenesis respectively
[10–12].
A number of cross sectional studies have reported the
association of NAFLD with chronic, subclinical general activation
of the hypothalamo-pituitary-adrenal (HPA) axis in humans [13–
15]. None of these studies however have undertaken a detailed
analysis of hepatic pre receptor cortisol metabolism in patients
with NAFLD. We propose that dysregulation of hepatic GC
metabolism may be critical in the pathogenesis and/or progression
of NAFLD with increased regeneration (11b-HSD1) or decreased
clearance (5a-reductase) contributing to the hepatic phenotype.
We have therefore performed a detailed characterisation (in vivo
and ex vivo) of GC metabolism in patients with NAFLD compared
with obese controls.
Materials and Methods
Human Subjects
Clinical studies were carried out on 16 patients recruited from
the multidisciplinary NAFLD clinic at University Hospital
Birmingham, with chronically elevated liver enzymes and evidence
of hepatic steatosis on ultrasound. The diagnosis of NAFLD was
made on histological analysis of clinically indicated biopsies after
exclusion of other possible etiological factors (alcohol intake of
.20 g/day, viral and autoimmune hepatitis and hepatototoxic
drugs). 8 patients had hepatic steatosis and 8 had steatohepatitis.
Renal function was normal and none were taking any drugs
known to interfere with the HPA axis (glucocorticoids, anticon-
vulsants, estrogen treatment). Five patients had well controlled
type 2 diabetes (2 steatosis patients on low dose metformin, 3
NASH patients – 2 on low dose metformin and one diet
controlled). Patients on metformin had stopped medication for 2
days before participating in the study.
32 healthy obese control volunteers (BMI.30 kg/m2) were
recruited by local advertisements. All had normal liver function
biochemistry (AST, cGT, ALT, ALP and bilirubin).
Separate from the clinical study participants, liver samples were
obtained from the liver tissue archive at the Centre for Liver
Research, University of Birmingham and were used for in vitro
gene and protein expression studies. These were all snap frozen
samples that had been collected during the previous 24 month
period, and stored at 280uC. All diagnoses were verified by
histological analysis (NASH n=5, normal transplant donor liver
n = 5).
Clinical Studies
Ethics Statement: The study and protocol received local ethics
committee (Solihull research ethics committee) approval and
written informed consent was obtained from all participants.
Patients were admitted to the research facility in the fasted state.
Resting blood pressure (mmHg) and anthropometric measure-
ments were taken (waist and hip circumference, BMI (kg/m2), and
sagittal height (cm)). Venous blood samples were taken for fasting
serum free fatty acids, liver function tests and other baseline
biochemical blood measurements as per standard laboratory
procedures.
Patients underwent body composition analysis using dual-
energy X-ray absorptiometry (DXA) with a total body scanner
(QDR 45OO; Hologic, Bedford, MA). Coefficients of variation
(CVs) for multiple scans were ,3%. Subcutaneous and visceral
abdominal fat distribution was measured using a single 10 mm
slice of computed tomography (CT) at the L3 vertebral level and
analysed using commercial software (MeVis PULMO 3D 3.11,
MeVIS Research GmbH, Bremen, Germany). A three dimen-
sional analysis was carried out on the scan from which the fat area
was calculated by dividing the volume results by the scan thickness.
Total fat area and visceral fat area regions of interest (ROIs) were
delineated by manually tracing a contour of each region. Fat pixels
and therefore fat area were identified with threshold attenuation
values between 250 to 2250 hounsfield units as described
previously [16]. The subcutaneous fat area was calculated by
subtracting the visceral from total fat area. Data was expressed as
1) total, subcutaneous and visceral fat area, 2) the ratio of visceral
to total fat (% visceral fat), 3) the ratio of visceral to subcutaneous
fat (V:S ratio). Patients also returned a 24 hour urine collection for
steroid metabolite analysis.
On a second day of investigation, patients took 1 mg of
dexamethasone orally at 2300h to suppress endogenous cortisol
production, and attended the Clinical Research Facility at 0800h
the following morning. After baseline 0900h measurements of
cortisol and adrenocorticotropic hormone, a further 0.5 mg of
dexamethasone and cortisone acetate (25 mg) were given orally.
Serum cortisol concentrations were then measured at 20-min
intervals for 240 min as previously reported [17].
Biochemical analysis
Blood count, urea, creatinine and electrolytes, cholesterol,
triglycerides, liver chemistry, and glucose were measured using
standard laboratory methods (Roche Modular system; Roche,
Lewes, U.K.). Plasma FFA were analysed on a COBAS BIO
semiautomatic analyser (La Roche, Basel, Switzerland) using a
NEFA-C Kit (Alpha Laboratories, UK).
Serum cortisol was assayed using a coat-a-count radioimmuno-
assay (Diagnostic Products, Los Angeles, CA) as per the
manufacturer’s guidelines. The ‘cortisol’ area under the curve
generated following cortisone acetate administration was used as
an index of hepatic 11b-HSD1 activity as previously described
[17].
Urine samples were analyzed by gas chromatography/mass
spectrometry, as reported previously [18,19], measuring free and
conjugated cortisol metabolites. The THF+5aTHF/THE, the
cortols/cortolones, and the 11OH-androsterone+11OH-etiochol-
anolone/11-oxoetiocholanolone ratios represent acknowledged
markers of global 11b-HSD1 activity, with a high ratio indicating
increased 11b-HSD1 reductase activity, with the proviso that the
Hepatic Cortisol Metabolism in NAFLD
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urinary free F/E (UFF/UFE) ratio, reflecting 11b-HSD2 activity is
normal. The 5aTHF/THF was used as a marker of 5a-reductase
activity with a high ratio in the setting of increased absolute levels
of urinary 5a-THF indicating increased activity.
Real Time PCR
11b-HSD1, Glucocorticoid receptor a (GRa), and 5a-reductase
2 (SRD5A2) hepatic mRNA levels were measured by real-time
PCR using an ABI 7500 system (Perkin-Elmer, Biosystems,
Warrington, UK). PCR was performed in 25 ml reactions on 96-
well plates. Reactions contained TaqMan universal PCR master
mix (Applied Biosystems, Warrington, Cheshire, UK), 900 nmol
primers, 100–200 nmol TaqMan probe and 25–50 ng cDNA. All
reactions were multiplexed with primers specific for 18S rRNA
(provided as a preoptimized mix; Perkin-Elmer, Beaconsfield,
Bucks, UK) as an internal reference. All target gene probes were
labelled with the fluorescent label FAM, and the 18S probe with
the fluorescent label VIC. Reactions were as follows: 50uC for
2 min, 95uC for 10 min, and then 40 cycles of 95uC for 15 s and
60uC for 1 min. Data were analysed according to the manufac-
turer’s guidelines and were obtained as Ct values (the cycle
number at which logarithmic PCR plots cross a calculated
threshold line) and used to determine dCt values (dCt =Ct of
the target gene minus Ct of the internal reference, 18S). Probes
and primers for all genes were provided by ‘assay on demand’
(Applied Biosystems). Arbitrary units were used with the
transformation [AU=1000*22dCt] to express results obtained.
Immunohistochemistry and Immunofluorescence
Five micron thick acetone fixed frozen liver sections with
severe NASH and normal donor livers were cut onto coated
glass slides. The slides were treated with methanol-hydrogen
peroxide 0.1% to block endogenous peroxidase activity for
20 minutes. After washing in phosphate buffered saline (PBS)
sections were incubated in 20% normal donkey serum for
30 minutes and then with polyclonal antibody to 11b-HSD1
[20] at a dilution of 1 in 100 in 10% donkey serum for
45 minutes. Secondary antibody, donkey antisheep IgG perox-
idase conjugate (1:200), was added to sections for 30 min. Slides
were developed using 3,39-diaminobenzidine and were counter-
stained with Mayer’s hematoxylin. Immunofluorescence was
carried out to detect co-localisation of 11b-HSD1 with the
CD68 macrophage marker (purified mouse anti human CD68,
BD Pharmingen). 11b-HSD1 primary antibodies were as
described above. Alexa Fluor 488 donkey anti sheep IgG and
Alexa Flour 546 rabbit anti mouse IgG were used at a dilution of
1:100 and slides were covered in foil for the remainder of the
procedure. Slides were mounted in VectaShield hard set
mounting medium with DAPI (Vector Labs).
Preparation of Liver Microsomes
Human liver microsomes were prepared from 4 human normal
livers and 5 livers with NASH livers by differential centrifugation
techniques as described previously [21]. Microsomal fractions
were resuspended in a buffer containing 20 mm NaCl, 1 mm
MgCl2, 100 mm KCl, 20 mm Mops, pH 7.2, and were snap-
frozen under liquid nitrogen. Microsomal protein concentration
was determined using the Bio-Rad protein assay with bovine
serum albumin as a standard as per the manufacturer’s
instructions (Bio-Rad). The integrity of the microsomal mem-
branes was assessed by using the mannose-6-phosphatase assay
[22], which showed a latency greater than 95% in all
preparations.
Immunoblotting
SDS-PAGE was performed by the method of Laemmli [23]
with 10 mg of liver microsomal protein on 11% acrylamide
minigels using a Bio-Rad Mini-PROTEAN II apparatus (Bio-
Rad). Following electrophoresis, proteins were transferred to
Immobilon-P membrane (Millipore Corp., Bedford, MA). Non-
specific protein binding was blocked by incubating membranes in
20% nonfat milk, 0.1% Tween 20 in phosphate-buffered saline at
25uC for 1 h. Membranes were then incubated with an in-house
raised polyclonal antibody to human 11b-HSD1 at a dilution of
1:1000 for 12 h at 4uC. Following 3610-min washes in phosphate-
buffered saline, 0.1% Tween 20, membranes were incubated with
secondary antibody (goat anti-sheep IgG peroxidase-conjugate) at
a dilution of 1:25,000 for 1 h at room temperature. Bound
peroxidase-conjugated IgG was visualized using ECL detection kit
(Amersham Biosciences, Buckinghamshire, UK) by exposing
membranes to x-ray film (Kodak, France). Membranes were
reprobed with anti-beta Actin antibody [mAbcam 8226] (HRP) as
a loading Control at 1:20,000.
Table 1. Baseline clinical characteristics of patients with
hepatic steatosis, NASH and controls.
Variable
Control
subjects Steatosis NASH
n 32 8 8
age (years) 4762.0 3763.0f 5462.0
BMI kg/m2 32.460.9 37.163.1 36.561.8
waist:hip ratio 0.960.01d 0.9660.1 1.060.03
sag height (cm) 23.360.6d 2261f 27.961.2
%Fat, 37.461.2a 29.762.8 36.162.5
% visceral fat 37.665.4 43.364.4 51.464.8
V:S ratio 0.660.1 0.8360.2 1.1760.2
Creat (mmol/L) 8963 9664 8964
Total cholesterol (mmol/L) 6.861.4 5.360.7 5.260.4
HDL cholesterol (mmol/L) 1.460.1 1.160.1 1.360.1
Triglycerides (mmol/L) 1.360.1bc 2.560.4 2.160.4
ALT (iu/L) 2462bd 93623 62613
ALP (u/L) 16667 170612 204630
AST (iU/L) 2260.9bd 4066 5168
cGT (iu/L) 2262bd 68621 119648
fasting FFA (mmol/L) 328617 431664 413636
fasting glucose (mmol/L) 4.760.1d 4.860.2e 6.560.7
Systolic blood pressure (mmHg) 13464 13362 13565
Diastolic blood pressure (mmHg) 7663 7765 7963
Cortisol post dex suppression
(nmol/L)
2665 1263 2665
Fasting insulin (mU/L) 9.761.8d 1665.1 2767.7
HOMA-IR 2.2160.5d 2.661.0 7.462.6
Data are presented as means 6 SE.
,Whole body fat measured by DXA. CT measured visceral and subcutaneous
fat.
acontrols vs steatosis p,0.05,
bcontrols vs steatosis p,0.01, controls vs NASH p,0.05,
dcontrols vs NASH p,0.01,
esteatosis vs NASH p,0.05,
fsteatosis vs NASH p,0.01. (Dex: dexamethasone).
doi:10.1371/journal.pone.0029531.t001
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Statistical Analysis
Data are presented as means 6 SE unless otherwise stated.
Area under the curve (AUC) analysis was performed using the
trapezoidal method. For comparison of single variables between
control, steatosis and steatohepatitis groups, one way analysis of
variance (ANOVA) was used to identify variables with
differences between groups and t tests were used (Mann
Whitney test was used where data were not normally
Figure 1. 24 hour urine steroid metabolite analysis from patients with steatosis and steatohepatitis compared with obese controls.
(A): 5a-reductase activity as depicted by the urinary 5aTHF/THF ratio (mean 6 SEM). (B): total 24 Urine 5a-reduced metabolites (mean 6 SEM)
(Andros: androsterone). (C): total 24 hr Urine F metabolites (mean 6 SEM).
doi:10.1371/journal.pone.0029531.g001
Hepatic Cortisol Metabolism in NAFLD
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distributed). Analysis was performed using SPSS Statistics 17.0
software.
Results
Clinical and biochemical characteristics of participants
We characterised the metabolic phenotype and hepatic cortisol
metabolism in patients with histologically proven NAFLD
compared to healthy obese control. Compared with the control
group, waist:hip ratios and sagittal height were significantly higher
in the NASH group. While % visceral fat was also highest in the
NASH group this did not achieve significance. Liver transaminases
were similar in both steatosis and NASH group and significantly
higher than controls. Insulin resistance using the HOMA-IR
model was highest in the NASH group. Baseline clinical and
biochemical characteristics of both groups are presented in
Table 1.
Urinary steroid metabolite analysis
24 h urinary steroid metabolite analysis by GC/MS demon-
strated increased cortisol clearance with higher 5aR (reflected by
urine 5aTHF/THF and An/Et ratios) in patients with hepatic
steatosis only, Figure 1A. 5a-, and not 5b-reduced metabolites
were increased in the steatosis group, Figure 1B. Absolute values
are presented in Table 2.
In addition, total urine cortisol metabolites were significantly
increased in patients with steatosis consistent with increased
glucocorticoid production rate, Table 2, Figure 1C. The urinary
THF+5aTHF/THE ratio was lower in the steatosis group and
elevated in the steatohepatitis group but this did not reach
statistical significance. However the cortols/cortolones ratio,
which also reflects 11b-HSD1 activity, was significantly reduced
in the steatosis group, Table 2, Figure 2A. Importantly the urine
UFF/UFE ratio was similar between groups indicating that
there was no difference in extrahepatic 11b-HSD2 activity,
Table 2.
Cortisol Generation Profiles
Endorsing the urinary steroid metabolite data, cortisol gener-
ation from oral cortisone was decreased in patients with steatosis
compared with controls. In contrast, patients with steatohepatitis
had significantly increased cortisol generation consistent with
increased hepatic 11b-HSD 1 activity compared with controls and
patients with steatosis, Figure 2B.
11b-HSD1 expression studies
Supporting the above data, 11b-HSD1 mRNA expression in
explant livers with NASH was significantly higher compared with
normal controls (dCT NASH 9.6560.29 vs 11.9660.29, p,0.01
NASH vs control), Figure 3A. SRD5A2 mRNA expression was
significantly decreased in NASH (dCT NASH 13.360.01 vs
1060.01, p,0.01 NASH vs control), Figure 3B and GRa mRNA
expression was significantly increased in NASH (dCT NASH
10.460.3 vs 11.760.3, p,0.05 NASH vs control), Figure 3C).
These results were further supported at the protein level by
immunohistochemistry; protein expression for 11b-HSD1was
increased in NASH livers compared with normals. Specifically,
intense staining was seen in hepatocytes in periseptal areas. There
was also intense staining in inflammatory cells within cirrhotic
nodules with morphology in keeping with macrophages. Immu-
nofluorescence studies confirmed these cells as CD68 positive cells
co-localising with 11b-HSD1 Figure 4 A–E. Immunoblotting for
11b-HSD1 of microsomal preparations of livers from patients with
NASH compared with normals did not show any significant
difference in expression, Figure 4F. This represents a discrepancy
between protein immunoblotting and mRNA expression in the
same samples. However the histological appearance of the NASH
samples provides some clues to the possible explanation for this.
When comparing protein expression by immunoblotting per mg of
liver microsomal protein, the overall 11b-HSD1 protein expres-
sion may be similar between normal and diseased groups because
the immunoblotting technique does not acknowledge localized
changes in expression.
Discussion
We have defined hepatic glucocorticoid metabolism in patients
with the full spectrum of NAFLD. In the early stages of NAFLD,
characterized by hepatic steatosis alone, hepatic cortisol clearance
predominates, driven by increased 5aR activity, and decreased
cortisol generation from 11b-HSD1 with a consequent activation
of the HPA axis and adrenal glucocorticoid production. With
disease progression and worsening inflammation and liver injury,
there is induction of hepatic 11b-HSD1 expression and activity
that increase hepatic glucocorticoid levels, with hepatic glucocor-
ticoid exposure maximized by increased expression of GRa and
decreased expression and activity of 5a-reductase. In steatohepa-
titis 11b-HSD1 expression is specifically intense in CD68 positive
macrophages, and may imply a role in response to chronic
inflammation. Collectively these results provide a key insight into
the pathophysiology of the NAFLD disease spectrum, with a
switch from inactivation to activation of hepatic glucocorticoid
levels as patients move from steatosis to NASH, Figure 5.
The first suggestion of a role of 11b-HSD1 in NAFLD
came with the observation that transgenic mice over expressing
Table 2. Urinary steroid metabolites and ratios in patients
with steatosis, NASH and control patients.
Steroid (mg/24 h) controls steatosis NASH
n 32 8 8
Cortisol 7167 7868 112620a
Cortisone 120611 127620 162639
THE 34266346 56266554 34476326c
THF 16246169 19736199 17596231
5a-THF 13246178 25006417a 14296300
a-cortol 316627 379642 496690a
b-cortol 457636 5336102 515697
a-cortolone 13036111 18996206a 17896256
b-cortolone 621657 8346112 641691
Total F metabolites 92666857 1394961075a 103516984d
Ratios
F/E 0.6160.03 0.6560.06 0.746012
(THF+5aTHF)/THE 0.8960.04 0.8160.06 0.9660.13
cortols/cortolones 0.4360.02 0.3360.02a 0.4260.04
5aTHF/THF 0.8460.07 1.3160.22a 0.9360.3
An/ET 1.1160.10 1.9960.31b 1.5560.6
Mean absolute values are shown (mg/24 h) +/2 SEM.
aP,0.05 vs controls,
bP,0.01 vs controls,
cP,0.05 vs steatosis,
dP,0.01 vs steatosis. (An: Androsterone, Et: Etiochoanolone, THE:
tetrahydrocostione, THF: tetrahydrocortisol).
doi:10.1371/journal.pone.0029531.t002
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11b-HSD1 in adipose tissue develop the full phenotype of the
metabolic syndrome including hepatic steatosis. Conversely
recombinant mice with global deletion of 11b-HSD1 are protected
from many of these features including hepatic steatosis [24,25].
Transgenic mice overexpressing the 11b-HSD1 gene selectively in
the liver under the transcriptional control of the human apoE
gene, exhibit fatty liver (but not steatohepatitis) with increased
hepatic triglyceride accumulation and impaired hepatic lipid
clearance [26]. Furthermore, selective 11b-HSD1 inhibition
reduced hepatic triglyceride concentration by nearly 30% and
increased in vivo hepatic fat oxidation and expression of related
genes in rats fed an obesogenic diet [27].
We postulate that the increase in hepatic cortisol clearance by
5a-reductases, and decreased 11b-HSD1 driven hepatic cortisol
generation in hepatic steatosis is a protective mechanism to
preserve hepatic metabolic phenotype by limiting hepatic cortisol
exposure and glucocorticoid induced deleterious effects. These
include ongoing hepatic lipogenesis, and gluconeogenesis with
increased glucose output which worsen hepatic and peripheral
insulin resistance. Indeed, recent work from our group has shown
a reduction in 5a-reductase activity with weight loss in otherwise
healthy obese subjects [28]. Women with polycystic ovarian
syndrome who are characterized by a susceptibility to the
metabolic syndrome also have increased 5a-reductase activity
and adrenocortical drive [29]. Both these groups of patients have
an increased propensity to develop NAFLD. Our data support
previously published findings of a subtle activation of the HPA axis
in patients with NAFLD, [13,14]. This may be secondary to the
increased clearance of hepatic glucocorticoid by the 5a-reductase
enzymes or reduction in11b-HSD1as shown in our steatosis
patients. Supportive in-vitro data with gene and protein expression
studies from steatotic human liver samples would be a valuable
extension for this work as such tissue becomes available.
In contrast, there is a clear drive to increase hepatic
glucocorticoid availability in steatohepatitis due to altered
regulation at multiple levels. These include reduced A ring
reductase mediated glucocorticoid clearance, increased glucocor-
ticoid receptor expression and increased 11b-HSD1 activity and
Figure 2. 11b-HSD1 activity assessed by: (A) 24 hr urine cortols/cortolones and 5aTHF+THF/THE ratios (mean 6 SEM) in patients with steatosis
and steatohepatitis compared with controls. (B) Hepatic cortisol generation measured by cortisol generation profiles (mean AUC 6 SEM) in patients
with steatosis and steatohepatitis compared with controls.
doi:10.1371/journal.pone.0029531.g002
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expression. 11b-HSD1 protein expression in NASH is increased
throughout the liver compared with controls. Increased GRa
expression (which is expressed homogenously throughout the liver
parenchyma in all hepatocytes without any specific zonal
distribution, [30]) would further maximize immediate effects of
increased hepatic glucocorticoid production. BMI data of
Figure 3. Real time PCR mRNA expression data on whole liver samples from 5 normal patients and 5 NASH patients (expressed as
arbitrary units ± SEM) for (A)HSD11B1 (11b-HSD 1), (B)SRD5A2 (5a-reductase 2), (C)GRa. ** p,0.01 NASH vs controls; * p,0.05 NASH vs
controls.
doi:10.1371/journal.pone.0029531.g003
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individuals from which the donor liver (normal control) samples
were obtained were not known, and it is possible that the BMI of
this group was lower than the obese control group used in the
clinical study. However, our previous work has shown that in
simple obesity, there is a reduction in the generation of serum
cortisol from dexamethasone-suppressed values after the admin-
istration of oral cortisone reflecting decreased hepatic 11b-HSD1
activity [9]. Hence it may be expected that hepatic 11b-HSD1
gene expression in simple obesity is also reduced compared with
non obese normal livers. Furthermore, in NASH livers 11b-HSD1
expression was specifically increased in hepatocytes in periseptal
areas and in CD68 positive macrophages within inflamed cirrhotic
septa. 11b-HSD1 expression was most intense in CD68 positive
macrophages, even more than in hepatocytes; collectively these
results would indicate a specific role for 11b-HSD1 glucocorticoid
production in the inflammatory process that occurs in NASH.
Previous studies have shown macrophage expression of 11b-HSD1
in the context of distinct disease models of acute inflammation
notably murine studies where macrophage 11b-HSD1 activity
rapidly increases during the development of acute peritonitis [31].
Our human study in NASH has shown for the first time that
macrophage 11b-HSD1 expression is specifically intense in a
chronic inflammatory process. These results clearly lead to a
number of exciting possibilities with respect to the role of
Figure 4. Hepatic 11b-HSD 1 immunoreactivity in patients with severe NASH compared to normal controls. There was generally
increased staining for 11b-HSD1 throughout the liver parenchyma in (A) NASH samples compared with (B) Normal liver620. (C) and (D) Increased
staining at the limiting plate in peri-septal areas and strongly staining specific cells within the inflammatory infiltrate in NASH610(C) and620(D) (E)
Confocal microscopy on severe NASH cryosections. Green - 11b-HSD1, red – CD68 IgG macrophage marker, yellow – colocalisation of 11b-HSD1 and
CD68 positive macrophages. (F) Western blot analysis of human liver microsomes from normal and NASH livers.
doi:10.1371/journal.pone.0029531.g004
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11b-HSD1 in steatohepatitis. With relevance to the inflammatory
response it would be important to discern the phenotype of the
response of these macrophages. Previous studies have shown that
macrophage 11b-HSD1 expression is stimulated by IL-4 and IL-3
cytokines, both examples of Th2 cytokines that promote anti
inflammatory responses. In the peritonitis model referred to above,
macrophage 11b-HSD1 expression was important in the induction
of phagocytosis of apoptotic neutrophils [31]. However, treatment
of a murine macrophage cell line with 11b-HSD1 inhibitors was
able to reduce the proinflammatory cytokine response following
lipopolysaccharide treatment [32]. Macrophage 11b-HSD1 me-
diated glucocorticoid production may therefore be a central
mechanism to fine tune the phenotype of the inflammatory
response. This may be to limit injury in chronic inflammation, and
promote pro resolution mechanisms particularly in acute inflam-
mation. The role of the differential activation of Type 1 (pro-
inflammatory), and Type 2 (anti-inflammatory) macrophages in
determining the outcome of liver inflammation has only recently
been appreciated [33]. Increased hepatocyte 11b-HSD1 expres-
sion, particularly in periseptal areas would further directly expose
inflamed septa to glucocorticoids. However overall increased
hepatic glucocorticoid would also promote hepatic lipogenesis and
hence be expected to worsen hepatic steatosis. Studies on other
tissues, including synovium from patients with rheumatoid arthritis
[34], human and rodent colitis [35], aortic smooth muscle cells
[36], and granulosa cells in the inflammatory response to ovulation
[37], all show a consistent picture of induction of cell specific 11b-
HSD1 gene expression in response to pro inflammatory cytokines,
TNFa and IL-1b being the most commonly implicated [38]. The
molecular mechanism by which 11b-HSD1 is induced in response
to cytokines is not entirely clear, but key transcription factors of the
C/EBP family play a crucial role [39,40].
Simple hepatic steatosis is a relatively benign entity in the
NAFLD disease spectrum with only a 2% risk of developing
progressive disease in a twenty year period. However, the presence
of fibrosis or inflammation at diagnosis is associated with a risk of
developing NASH cirrhosis of up to 50% in a two year period [1].
The factors implicated in the crucial switch between simple
steatosis and NASH are not entirely clear. Increased liver fat is
pivotal to inflammation in NAFLD, and thus the increased supply
of free fatty acids to the liver, associated with adipose tissue insulin
resistance and obesity is a key factor in the development of hepatic
inflammation in NAFLD. Our data show increased fasting serum
FFA in patients with NAFLD compared with controls although
this not achieve significance as in previously described studies.
Adipose tissue insulin resistance may occur in obesity in part
through the infiltration of macrophages which release pro
inflammatory cytokines such as TNFa, IL-6 and IL1b [41]. Once
FFA are taken up by the liver, as well as being oxidized and stored
as triglyceride, they activate the transcription factor NFkB, a key
regulator of gene transcription of proinflammatory cytokines,
adhesion molecules, and chemokines [42]. What results is a cycle
of hepatic injury and inflammation. The cytokines released from
hepatocytes, in particular TNFa activate classic inflammatory
cells, as well as Kupffer cells which generate more cytokines,
further contributing to hepatic oxidative stress by promoting FFA
oxidation, which enhances the hepatic injury that occurs by
cytokine driven hepatocyte apoptosis and necrosis [43].
The histological appearance of NASH and alcoholic steatohe-
patitis are similar. Fatty change is also commonly seen in hepatitis
Figure 5. Schematic: Hepatic glucocorticoid metabolism and its modulation in response to disease progression in NAFLD.
doi:10.1371/journal.pone.0029531.g005
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C infection and in some cases is associated with steatohepatitis.
Our in vivo studies showed increased hepatic glucocorticoid
generation in patients with alcoholic liver disease [44] suggesting
that 11b-HSD1 may be increased in steatohepatitis regardless of
the underlying cause. Longitudinal studies investigating the role of
hepatic 11b-HSD1 in disease progression and outcome of hepatic
steatosis would provide valuable data.
This work has defined hepatic glucocorticoid metabolism in
progressive NAFLD, which can be summarized into two distinct
phases of altered regulation of hepatic cortisol metabolism;
increased hepatic cortisol clearance in steatosis, and increased
hepatic cortisol regeneration in NASH. Failure to regulate in this
way may worsen the phenotype of liver disease i.e. drive hepatic
steatosis or unchecked progressive hepatic inflammation. This is
an exciting area of investigation that clearly warrants further study
but may impact upon the role of selective 11b-HSD1 inhibitors in
the treatment of patients with the Metabolic Syndrome. 11b-
HSD1 inhibition may be favorable in treating hepatic steatosis by
limiting hepatic lipid deposition, but paradoxically may worsen an
inflammatory response in the presence of NASH. Hence the
therapeutic benefit of 11b-HSD1 inhibition may critically depend
on the histological stage of NAFLD.
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